New biomarkers could help doctors spot Alzheimer's and other neurodegenerative diseases

Aug 11, 2006

Neurodegenerative diseases like Alzheimer's and Parkinson's in their early stages can be difficult for physicians to spot, and many diagnoses are incorrect. A finding by researchers at the University of Washington and Harborview Medical Center may soon help in the diagnosis of such diseases.

The researchers have used an advanced technique to identify proteins in the human body, known as biomarkers, that can indicate whether a patient has a particular neurodegenerative disease, or determine the progression of a disease. Searching for biomarkers is nothing new, but the researchers used a cutting-edge proteomics system, called iTRAQ, that relies on isotopic labeling of protein molecules. The system could help a physician determine the amount of a biomarker a patient may have in his body, which can help with diagnosis.

In a large multi-site study, the researchers identified more than 1,500 potential biomarkers in cerebrospinal fluid from patients with one of three neurodegenerative diseases: Alzheimer's, Parksinson's, or dementia with Lewy bodies (DLB). Researchers identified different sets of potential biomarkers corresponding to each disease; each of the proteins are linked specifically to one of the diseases. The results appear in the new issue of the Journal of Alzheimer's Disease.

"We're getting very close to being able to use these biomarkers for the clinical diagnosis of Alzheimer's and Parkinson's disease, and dementia with Lewy bodies," said the study's lead author, Dr. Jing Zhang, associate professor of pathology at the UW. His lab is at Harborview Medical Center. "This is a major improvement on other biomarker detection techniques."

Alzheimer's, Parkinson's, and other neurodegenerative diseases affect millions of people in the United States, and the toll of the diseases is expected to worsen as the Baby Boomer generation grows older. Though researchers and clinicians are learning more and more about the diseases, there is still uncertainty in the diagnosis and treatment of these conditions.

The biomarkers identified in this study need to be tested in a larger population of patients before becoming part of a full diagnostic tool, Zhang said, but these results are promising. The extensive number of proteins that the research team found in patients with neurodegenerative diseases will likely help researchers create a large panel of biomarkers that could be used in a clinical diagnosis and in monitoring disease progression.

The multi-site study also included researchers from Oregon Health and Science University in Portland; Baylor College of Medicine in Houston; the Fred Hutchinson Cancer Research Center in Seattle; and Applied Biosystems in Framingham, Mass.

Source: University of Washington

Explore further: FDA approves AbbVie combo hepatitis C treatment

add to favorites email to friend print save as pdf

Related Stories

Ag-tech could change how the world eats

3 hours ago

Investors and entrepreneurs behind some of the world's newest industries have started to put their money and tech talents into farming - the world's oldest industry - with an audacious agenda: to make sure there is enough ...

World's rarest cetacean threatened by illegal gillnets

3 hours ago

The world's rarest cetacean could disappear in less than four years unless immediate action is taken by the Mexican government to protect it from entanglement in gillnets deployed illegally in its Gulf of California refuge, ...

Enviro-tracker is wearable for citizen monitoring

4 hours ago

Mobile hardware and software allow us to count our steps, and to count our calories, but a Vancouver, Canada, startup group asked, what about tracking our environment? TZOA was founded in 2013. Laura Moe, ...

In Curiosity Hacked, children learn to make, not buy

4 hours ago

With her right hand, my 8-year-old daughter, Kalian, presses the red-hot soldering iron against the circuit board. With her left hand, she guides a thin, tin wire until it's pressing against both the circuit board and the ...

Recommended for you

FDA OKs Cubist antibiotic for serious infections

4 minutes ago

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.